LNC
ITRM

Lincoln National Corp’s Iterum Therapeutics ITRM Stock Holding History

Lincoln National Corp’s Portfolio ITRM Stock Details ITRM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-667
Closed -$23K – 883
2021
Q2 		$23K Buy
+667
New +$14.5K ﹤0.01% 853

Other funds holding ITRM

CPX
Canaan Partners X Menlo Park, California $74.7M AUM 151.56% 1-Year Est. Return
NLVP
New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
FNBT
FineMark National Bank & Trust Fort Myers, Florida $3.2B AUM 18.28% 1-Year Est. Return
GC
Grimes & Company Westborough, Massachusetts $4.62B AUM 29.71% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return

Lincoln National Corp's ITRM Position: Q3 2021 in Review

Lincoln National Corp sold out of Iterum Therapeutics (ITRM) in Q3 2021, closing a stake of 667 shares — an estimated $23K sold.

Lincoln National Corp first reported a position in ITRM in Q2 2021 and held it in 1 quarter. The position peaked at $23K in Q2 2021. 42 funds tracked by Wall St. Rank hold ITRM as of Q3 2021.

  • Lincoln National Corp reported no remaining Iterum Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Lincoln National Corp sold 667 Iterum Therapeutics shares in Q3 2021, an estimated $23K.
  • Lincoln National Corp first reported a position in Iterum Therapeutics in Q2 2021 and held it in 1 quarter.
  • Lincoln National Corp's Iterum Therapeutics position peaked at $23K in Q2 2021.
  • 42 funds tracked by Wall St. Rank held Iterum Therapeutics as of Q3 2021.

Based on Lincoln National Corp's 13F filing for Q3 2021, filed 5 Nov 2021.